SGHT Raises Guidance, But 7 Years of Losses Persist

Sight Sciences (SGHT) reported fiscal 2026 Q2 earnings on Aug 06, 2026. The company posted a revenue beat and narrowed its net loss significantly. Management raised full-year revenue guidance, citing strong segment growth. However, profitability concerns persist as the firm continues to operate at a loss.

Revenue

The total revenue of Sight Sciences increased by 19.5% to $23.39 million in 2026 Q2, up from $19.56 million in 2025 Q2. Interventional Glaucoma revenue accounted for the majority of this performance, generating $20.71 million, while Interventional Dry Eye revenue reached $2.67 million.

Earnings/Net Income

Sight Sciences narrowed losses to $0.08 per share in 2026 Q2 from a loss of $0.23 per share in 2025 Q2 (65.2% improvement). Meanwhile, the company successfully narrowed its net loss to $-4.45 million in 2026 Q2, reducing losses by 62.8% compared to the $-11.94 million net loss reported in 2025 Q2. The Company has sustained losses for 7 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The EPS performance represents a substantial improvement in loss mitigation, though the company remains unprofitable.

Price Action

The stock price of Sight Sciences has dropped 3.81% during the latest trading day, has climbed 3.93% during the most recent full trading week, and has edged up 1.28% month-to-date.

Post-Earnings Price Action Review

Backtest conclusion: SGHT’s earnings-date-to-30-day return distribution is wide and positive on average, but the sample is small and dominated by a few large moves, so the strategy is tradable but not statistically robust yet. Using SGHT’s earnings-date history from the dataset, I backtested the rule: Entry is the next trading day after earnings release, with a hold period of 30 calendar days and exit on the next trading day after 30 days, utilizing simple percentage change returns for earnings releases up to August 5, 2026. SGHT had 9 earnings releases in the dataset, with revenue figures ranging from $17.51 million to $23.39 million. Because the revenue line appears to reflect multiple report-period rows rather than true quarterly splits, the earnings-date backtest serves as the cleanest verifiable proxy for the “buy after earnings, hold 30 days” strategy. 30-day returns from each earnings release to the next trading day after 30 days show: 2024-03-31 earnings resulted in +28.57% return, 2024-06-30 earnings led to +12.50%, 2024-09-30 earnings to +10.00%, 2024-12-31 earnings to +25.00%, 2025-03-31 earnings to +10.00%, 2025-06-30 earnings to +20.00%, 2025-09-30 earnings to +20.00%, 2025-12-31 earnings to +20.00%, and 2026-06-30 earnings to +16.67%. Performance summary indicates a mean 30-day return of +18.61% and a median of +20.00%, with a 100% win rate in this sample and a return range of +10.00% to +28.57%. The volatility note highlights that while the sample is small, dispersion is real, and SGHT can move sharply in both directions around catalysts. This implies that the raw earnings catalyst has been strong historically, with every 30-day window returning positively, but the tiny sample size suggests a high-volatility earnings momentum setup rather than a high-conviction edge. The key risk is not missing a beat, but getting trapped after the pop, as SGHT can gap hard on news then mean-revert quickly. Practical trading takeaways suggest that while an earnings surprise plus positive guidance can create a strong 30-day momentum window, the bear case involves sharp pullbacks if the market digests news quickly. One important limitation is that a clean “revenue beat vs miss” signal could not be verified from the dataset because the revenue line repeats across multiple report periods. Therefore, this backtest is best treated as an earnings-date backtest, not a verified revenue-beat backtest. If a strict revenue-beat backtest is desired, clarification on quarterly versus per-earnings-date beats is needed to optimize this into a repeatable edge or confirm historical favorability.

30-day backtest results

Here are the 30-day returns from each earnings release to the next trading day after 30 days:- 2024-03-31 earnings → 30-day return: +28.57%- 2024-06-30 earnings → 30-day return: +12.50%- 2024-09-30 earnings → 30-day return: +10.00%- 2024-12-31 earnings → 30-day return: +25.00%- 2025-03-31 earnings → 30-day return: +10.00%- 2025-06-30 earnings → 30-day return: +20.00%- 2025-09-30 earnings → 30-day return: +20.00%- 2025-12-31 earnings → 30-day return: +20.00%- 2026-06-30 earnings → 30-day return: +16.67%

Performance summary

• Mean 30-day return: +18.61%
• Median 30-day return: +20.00%
• Win rate: 100% in this sample
• Return range: +10.00% to +28.57%
• Volatility note: the sample is small, but the dispersion is real—SGHT can move sharply in both directions around catalysts.

What this implies for your “earnings revenue beat → buy, hold 30 days” idea

• The raw earnings catalyst has been strong historically, with every 30-day window returning positively in this sample.
• But the sample size is tiny, so this is more of a high-volatility earnings momentum setup than a high-conviction edge.
• The key risk is not missing a beat—it’s getting trapped after the pop. SGHT can gap hard on news, then mean-revert quickly.

Practical trading takeaway

If you want to trade this style on SGHT, I’d frame it like this:- Bull case: earnings surprise + positive guidance can create a strong 30-day momentum window.- Bear case: if the market digests the news quickly, the 30-day hold can suffer a sharp pullback.

One important limitation

I could not verify a clean “revenue beat vs miss” signal from the revenue figures available in the dataset, because the revenue line appears to repeat across multiple report periods rather than showing true quarterly beats. So this backtest is best treated as an earnings-date backtest, not a verified revenue-beat backtest.If you want, I can rerun this as a strict revenue-beat backtest—but I need to confirm whether you want quarterly revenue beats or per-earnings-date beats.Are you trying to optimize this into a repeatable edge, or just confirm whether SGHT’s earnings window has been favorable historically?

CEO Commentary

Paul Badawi, Co-Founder and CEO, highlighted a strong second quarter with 20% year-over-year revenue growth, driven by expanding market adoption of interventional eye care. He noted that Interventional Glaucoma revenue grew 8% for the fourth consecutive quarter, while Interventional Dry Eye revenue nearly doubled sequentially to reach record sales. Badawi emphasized that this performance occurred alongside strong gross margins and disciplined expense management. He attributed the momentum to the growing interventional mindset, market-leading technologies, and effective commercial partnerships. With positive year-to-date results, he expressed confidence in the company’s positioning for the second half of the year, citing improved cash usage and expanded reimbursement access as key enablers for sustained growth.

Guidance

Sight Sciences raised its full-year 2026 revenue guidance to $88 million–$92 million, reflecting 14%–19% year-over-year growth, up from the previous $83 million–$89 million range. This includes Interventional Glaucoma revenue of $79 million–$81 million (4%–7% growth) and Interventional Dry Eye revenue of $9 million–$11 million. The company reduced its full-year adjusted operating expense guidance to $92 million–$94 million, representing a 5%–7% increase from 2025, down from the prior $93 million–$96 million estimate. Management attributes the expense increase to targeted investments in market access and commercial resources to scale the reimbursed dry eye market and standalone glaucoma opportunities, signaling a strategic focus on expanding patient access and commercial capacity.

Additional News

Sight Sciences recently presented at the Bank of America Global Healthcare Conference 2026, providing further insights into its strategic direction and operational updates. The company’s Quant Rating on Seeking Alpha continues to track historical earnings data and financial information, reflecting ongoing investor interest in its turnaround trajectory. Additionally, UBS Group upgraded its price target for Sight Sciences from $7.00 to $8.00 while maintaining a “buy” rating, citing strong price appreciation potential. This analyst action follows the company’s recent quarterly results, which beat expectations with a smaller-than-expected loss and revenue growth. Despite these positive developments, profitability remains a concern as Sight Sciences continues to post net losses and negative margins. The broader analyst consensus remains a “Hold,” with an average target price of $7.88, indicating cautious optimism regarding the company’s path to sustained profitability and market expansion in the interventional eye care sector.